INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 36 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $3,118,000 | 0.0% | 5,175,000 | 0.0% | 0.07% | +7.4% |
| Q4 2021 | $3,118,000 | -75.8% | 5,175,000 | -74.2% | 0.07% | -86.7% |
| Q1 2021 | $12,862,000 | -63.0% | 20,093,000 | -64.1% | 0.51% | -61.4% |
| Q4 2020 | $34,742,000 | -11.1% | 55,943,000 | 0.0% | 1.33% | -36.8% |
| Q3 2020 | $39,071,000 | +93.0% | 55,943,000 | +100.2% | 2.11% | +22.3% |
| Q2 2020 | $20,241,000 | +24.2% | 27,943,000 | +55.2% | 1.72% | -27.6% |
| Q3 2019 | $16,303,000 | -18.1% | 18,000,000 | -10.0% | 2.38% | +80.9% |
| Q2 2019 | $19,894,000 | – | 20,000,000 | – | 1.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 9,295,000 | $12,549 | 3.76% |
| Context Capital Management, LLC | 23,076 | $22,612 | 1.81% |
| Weiss Asset Management LP | 16,160,000 | $15,847,974 | 0.94% |
| Anson Funds Management LP | 4,000,000 | $3,920,000 | 0.79% |
| SYQUANT CAPITAL SAS | 2,000,000 | $1,961 | 0.77% |
| DG Capital Management, LLC | 1,101,000 | $1,082,834 | 0.59% |
| Skaana Management L.P. | 2,000,000 | $1,957,600 | 0.48% |
| AQR Arbitrage LLC | 6,130,000 | $6,046,019 | 0.27% |
| OAKTREE CAPITAL MANAGEMENT LP | 7,295,000 | $7,195,058 | 0.10% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $220,658 | 0.04% |